Welcome to our dedicated page for Mesoblast SEC filings (Ticker: MEOBF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Mesoblast Limited (MEOBF) SEC filings page provides access to the company’s U.S. regulatory disclosures as a foreign private issuer incorporated in Australia. Mesoblast Limited files annual reports under cover of Form 20-F and furnishes current information on Form 6-K pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.
Mesoblast’s Form 6-K submissions typically attach documents first filed with the Australian Securities Exchange (ASX). These include new issue announcements, notifications of issue, conversion or payment up of unquoted equity securities (Appendix 3G), applications for quotation of securities (Appendix 2A), notifications of cessation of securities (Appendix 3H), proposed issues of securities (Appendix 3B), and change of director’s interest notices (Appendix 3Y), as well as press and news release announcements.
Through this page, users can review how Mesoblast Limited reports on equity securities activity, including issuances, proposed issues, cessations, and applications for quotation, and how it discloses changes in directors’ holdings in its securities. These filings are relevant for investors tracking capital structure developments, director share transactions, and formal corporate announcements.
Stock Titan enhances these filings with AI-powered tools that help explain the structure and contents of lengthy documents. While the original Form 20-F and 6-K texts remain the authoritative sources, AI summaries can highlight key sections, such as equity changes or director interest updates, and make it easier to navigate the exhibits attached from the ASX. Real-time updates from EDGAR ensure that new Mesoblast Limited filings appear promptly, giving users a structured way to follow the company’s regulatory history.
Mesoblast Limited, an Australia-incorporated company, submitted a Form 6-K as a foreign private issuer. The report forwards a news release announcement that Mesoblast filed with the Australian Securities Exchange on November 5, 2025, attaching it as Exhibit 99.1 and incorporating it by reference.
The filing is signed on behalf of Mesoblast Limited by Company Secretary Paul Hughes, dated November 5, 2025.
Mesoblast Limited furnished a Form 6-K to provide investors with Australian Securities Exchange materials. The filing attaches two ASX documents dated October 28, 2025: an Appendix 3Y change of director’s interest notice and an Appendix 3G notification of issue, conversion or payment up of unquoted equity securities, incorporated by reference as Exhibits 99.1 and 99.2.
This update is administrative, making the ASX disclosures available to U.S. investors under the Exchange Act.
Mesoblast Limited furnished a Form 6-K detailing the availability of key shareholder materials filed with the Australian Securities Exchange. The submission includes the company’s Annual Report to Shareholders, a Notice of Annual General Meeting, and an Appendix 4G with Corporate Governance Statement, each attached as Exhibits 99.1, 99.2, and 99.3 and incorporated by reference.
Mesoblast reports as a foreign private issuer and files annual reports under Form 20-F. The filing identifies Australia as the jurisdiction of incorporation and lists the principal office at Level 38, 55 Collins Street, Melbourne 3000, Australia. The report was signed by Company Secretary Niva Sivakumar on October 28, 2025.
Mesoblast Limited furnished a Form 6-K to provide investors with its Australian Securities Exchange Appendix 4C quarterly report for the quarter ended September 30, 2025. The Appendix 4C is attached as Exhibit 99.1 and incorporated by reference. The filing is an administrative submission linking U.S. investors to the company’s ASX quarterly cash flow and activities report.
Mesoblast Limited furnished a Form 6-K noting that, on October 15, 2025, it filed several announcements with the Australian Securities Exchange. The report attaches and incorporates by reference four ASX documents: Appendix 3G (notification of issue, conversion or payment up of unquoted equity securities), Appendix 3H (notification of cessation of securities), Appendix 3Y (change of director’s interest notice), and Appendix 2A (application for quotation of securities).
The exhibits are labeled 99.1 through 99.4 and the report is signed by Company Secretary Niva Sivakumar.
Mesoblast Limited submitted a Form 6-K as a foreign private issuer for October 2025. The report states that on October 7, 2025, the company filed a news release announcement with the Australian Securities Exchange, which is attached as Exhibit 99.1 and incorporated by reference. The filing itself mainly serves to furnish this press release to U.S. investors.
Dr. William Gueck reported beneficial ownership of 64,521,900 Ordinary Shares of Mesoblast Ltd held in the form of American Depositary Receipts (ADRs), representing approximately 5.0% of the company's outstanding Ordinary Shares based on 1,281,167,187 shares outstanding. He is the sole beneficial owner of 525,000 ADRs and reports discretionary authority over additional ADRs held by family members, trusts and entities, including 49,717,450 ADRs held by Cova Holdings LP, 350,000 ADRs underlying exercisable warrants held by Cova Holdings LP, and 8,345,150 ADRs held by AVCO Holdings LP. The filing disclaims admission of beneficial ownership of shares held by the identified entities.
Mesoblast Limited submitted a Form 6-K as a foreign private issuer to provide U.S. investors with information simultaneously released in its home market. On September 15, 2025, the company filed a news release with the Australian Securities Exchange, which is attached to this report as Exhibit 99.1 and incorporated by reference.